In a safety update, the US Food and Drug Administration announced that information about the risk of atypical fractures of the thigh in patients who take bisphosphonates for osteoporosis must be added to the "warnings and precautions" section of the drugs' labels.
In a safety update, the US Food and Drug Administration (FDA) announced that information about the risk of atypical fractures of the thigh (ie, subtrochanteric and diaphyseal femur fractures) in patients who take bisphosphonates for osteoporosis must be added to the "warnings and precautions" section of the drugs' labels.
Only those bisphosphonates that have been approved to treat osteoporosis-not those used to treat Paget's disease or cancer-related hypercalcemia-are affected by this safety notice. These drugs include Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast and their generic equivalents.
Atypical fractures of the thigh, which account for fewer than 1% of all hip and femur fractures, may be related to long-term bisphosphonate use; optimal duration of bisphosphonate use to treat or prevent osteoporosis is unknown.
The agency also has mandated that pharmacists will give a medication guide about bisphosphonates to patients picking up their prescriptions.
The guide will describe the symptoms of atypical femur fracture and recommend that patients who develop symptoms notify their healthcare professional.
US Food and Drug Administration. FDA drug safety communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. http://www.fda.gov/drugs/drugsafety/ucm229009.htm. Accessed November 3, 2010.
Fasting glucose at GDM diagnosis may predict postpartum glucose abnormalities
February 6th 2025A recent study suggests that elevated fasting glucose levels at the time of gestational diabetes diagnosis could be an early indicator of postpartum glucose intolerance, emphasizing the need for close monitoring after delivery.
Read More
Ulipristal plus misoprostol shows promise for medication abortion
February 5th 2025A recent study found that ulipristal acetate followed by misoprostol is a safe, effective, and acceptable option for medication abortion, offering a potential alternative in areas with limited access to mifepristone.
Read More
Identification and management of patients at increased risk for breast cancer
February 5th 2025With breast cancer being the most diagnosed invasive cancer in the United States, OB-GYN practitioners play a crucial role in identifying high-risk patients and guiding them through screening, prevention, and risk-reduction strategies.
Read More